
A post hoc, unmatched comparison presented at ACAAI 2026 found similar 14-day improvements in urticaria activity with omalizumab vs remibrutinib.
This summary of March 2026 highlights key news and developments in the dermatology news space.
The month of March 2026 highlighted a variety of key news headlines within the dermatology space, including many resulting from the






